

RELTIO

SOLUTION BRIEF

Reltio for Clinical Operations

Using trusted data to bring life-saving therapies to market faster.




Accelerate R&D and clinical trials

85% of all clinical trials experience delays due to poor data quality, costing companies up to \$8M every day. To grow and thrive in today's digitized world, life sciences companies must transform their clinical operations to meet new expectations and optimize processes while complying with increased regulation and transparency requirements. This includes taking advantage of technology innovations enabling virtual clinical trials with remote data collection and enhanced recruitment of study participants, using analytics to identify the best sites, investigators, and patients. But fragmented, outdated data gets in the way.

Without a comprehensive and trusted source of truth for your core data, such as clinical studies, sites, and principal investigators, it is time consuming to gather needed data—and difficult to deliver critical insights that can make the difference between the success and failure of your clinical studies. Poor data quality can slow the drug R&D life cycle and limit innovation. Ultimately, this delays getting life-changing therapies to the patients who need them. And, of course, it hampers revenue growth, increases costs, and makes regulatory compliance more cumbersome.

It doesn't have to be this way. [Reltio Connected Data Platform](#), our AI-powered, cloud-native SaaS master data management (MDM) platform, unifies, standardizes, and enriches multisource data into a trusted source of information for your operational and analytical systems. Part of our core platform, Reltio for Life Sciences velocity pack delivers an industry-specific data model and configurations so you can speed your time to value.

Reltio for Life Sciences streamlines clinical trials



Conduct successful clinical trials with insight-ready data

Reltio Connected Data Platform unifies data about investigators, sponsors, clinical sites, drugs, and more so you can activate clinical performance analytics with study site and PI past performance, ratings, and competitive information from multiple sources. You can analyze for “clusters” where investigators congregate and match diversity and inclusion characteristics. Your R&D teams and CROs can efficiently define site selection criteria, search for available participants, and select them based on up-to-date metrics and qualitative criteria.

In addition to segmentation, with actionable data fueling your analytical and cognitive systems, you can make better and faster decisions in program management, quickly identify issues, and predict site performance—enabling on-time, on-budget, effective trials.

Clinical study with therapeutic areas

The screenshot displays the RELTIO interface for a search query. The search criteria are: Type: Clinical Study, Disease/Conditions: Oncology: Lung, Non-Small Cell. The results table is as follows:

Profile	Study Id	Start Date	Disease/Conditions	Therapeutic Area	Phase	Drug
LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung	300912	05-11-2017	Oncology: Lung, Non-Sm	Oncology	II	intensity-modulated etoposide
A Modular, Multi-arm, Multi-part, First Time in Patient Study to Eva	300707	08-08-2017	Oncology: Head/Neck Oncology: Esophageal	Oncology	I/II	
A Phase III, Randomized, Global Trial of Nivolumab and Epacadostat	298594	12-27-2017	Oncology: Lung, Non-Sm	Oncology	III	nivolumab epacadostat
Phase Ia/Iia Dose Escalation Trial to Determine Safety, Tolerance, and	298444	02-01-2017	Oncology: Cervical Oncology: Colorectal	Oncology	I/II	AVID-100
Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for	298425	02-24-2017	Oncology: Esophageal Oncology: Lung, Non-Sm	Oncology	I	radiation therapy carboplatin
Observation Study of Patients With Non-Small Cell Lung Cancer an	298415	02-24-2017	Oncology: Esophageal Oncology: Lung, Non-Sm	Oncology	IV	paclitaxel carboplatin
An Open-label, Single-arm Phase II Safety Study of Nivolumab in P	298272	05-26-2017	Oncology: Lung, Non-Sm	Oncology	II	nivolumab
A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in	298103	12-13-2017	Oncology: Lung, Non-Sm	Oncology	II	crizotinib
A Global, Randomised, Phase III, Open-label Study of REGN2810 (O	298046	05-29-2017	Oncology: Lung, Non-Sm	Oncology	III	cemiplimab
A Phase I/II Study of Ceritinib + Trametinib in Patients With Advan	297984	09-09-2017	Oncology: Lung, Non-Sm	Oncology	I/II	trametinib ceritinib


Reltio for Life Sciences accelerates time to value

Reltio for Life Sciences velocity pack offers an industry-specific canonical data model with the entity types, attributes, relationship types, and reference data your business needs to unify and gain a 360 view of your critical data. Our out-of-the-box data model includes sponsor, provider organization, investigator, clinical study, study site, and HCO (facility), and patient. You can easily extend the data model to support your specific requirements.

Our velocity pack also includes prebuilt configurations—driven by best practices—for cleansing, matching, survivorship, and the UI. And we offer an industry-first, pretrained life-sciences-specific ML model for match/merge, which further accelerates implementation time and enables accurate entity resolution with minimized effort. So you can jumpstart your implementation and be sure you have the most accurate and complete data possible.


We provide data enrichment with prebuilt integration to data tenant services for NPI, DEA, and 340B—available as an add-on. As well as prebuilt batch integration to MedPro. And our API-led connectivity and no-code/low-code integration environment allow fast integration development with third-party data sets.

Also, our prescriptive implementation methodology and predefined implementation assets further reduce your time to implement—typically with key functionality and important milestones live within 90 days. In short, our velocity pack helps you get up and running faster and easier, lowering your time to value and TCO.



Relationship management connects the dots

With our relationship management capabilities, powered by [Connected Graph](#) technology, you can discover and visualize affiliations and how sponsors, investigators, clinical sites, clinical studies, drugs, and therapeutic areas are connected—often in many-to-many relationships. So you can quickly identify content preferences, influence in a disease area, prescribed products, and clinical trial participation. You can improve relationships with targeted investigators for greater clinical research loyalty over multiple studies while accelerating both site selection and study enrollment.



Relationship Types

- HCO Enterprise Hierarchy
- HCO Affiliations
- HCP is Affiliated With HCO
- HCP is administrator of HCO
- HCO has address
- HCP has address
- Organization has address
- Investigator (HCP to Study)
- Sponsor (Organization to Study)
- Site to Trial
- Site to Investigator (Site to HCP)
- Site to Facility (Site to HCO)
- Patient to Clinical Study (Research Subject)

Interaction Types

Generic interactions:

- Website Login
- Mobile / App Login
- Call Center Engagement

Reference Data

- Address Type
- Email Type
- Phone Type
- Speciality
- Taxonomy
- Identifier Type
- Status
- Policy Consent Type
- Multi Channel Type
- Channel Consent
- Professional Activity
- Professional Designation
- Professional Degree
- License Type
- Study Type
- Therapeutic Area

Achieve recruitment goals faster

Reaching recruitment goals—a major success factor for clinical trials—involves increasing the potential pool of study sites, PIs, and patients. Decentralized clinical trials are becoming mainstream, enabled by wearable technologies and remote monitoring. This removes the limitation of distance from the clinical sites and expands the recruitment candidate pool for studies. And looking beyond geographic areas and including under-served populations to increase the diversity of ethnic, racial, and socioeconomic backgrounds have become critical factors impacting whether a study would be launched, put on hold, or canceled. A clear view into local populations that PIs serve speeds up the recruitment of a diverse group of patients.

Benefits

- Streamline planning and execution of clinical trials
- Spend less time and manual effort to assemble data from multiple systems to prepare clinical study submissions
- Increase productivity, collaboration, and efficiency
- Simplify compliance with regulations and approval processes
- Reduce the risk of expensive recalls and legal action
- Achieve fast time to value with industry-specific solution and ML-powered, pretrained matching

Capabilities

- AI-powered, cloud-native, SaaS MDM
- Unified, cleansed single source of truth from multisource data
- Prebuilt industry data model, configuration, and integration with NPI, DEA, 340B, and MedPro as add-ons
- Rapid integration using API-led and no-code/low-code tools
- HIPAA-compliant and HITRUST-certified
- Support for IDMP and data privacy compliance
- Continuous, automated data quality management with ML-powered anomaly detection

Reduce the cost of compliance and reporting

Our platform is HIPAA-compliant and HITRUST-certified, so you know the privacy, security, and integrity of your protected health information (PHI) is assured. We also protect personally identifiable information (PII) and sensitive PII to enable compliance with GDPR, CCPA, and other data privacy regulations, supported by built-in consent management.

Timely, trusted data drives more streamlined, effective clinical trials, leading to smoother and faster FDA reporting and approval. Your clinical teams spend significantly less time and manual effort to assemble data held in disparate internal systems and analyze the data needed to prepare complete, accurate, and high-quality clinical study submissions. They realize increased productivity and collaboration, with less rework due to shared, easy-to-access information, leading to lower clinical costs and greater output from your clinical studies organization.

We provide consolidated product data with a 360-degree view of the drug or medical device throughout its life cycle, from initial discovery in clinical testing to product approval through commercialization. Going beyond clinical studies, we [simplify IDMP compliance](#) by integrating data for substances, product definitions, organizations, and reference data to create a product 360 view and the framework for exchanging data with regulators.

Our unified, high-quality data and robust reporting with historical data, audit logs, and tracking of data lineage is the foundation for other regulatory reporting as well—the Sunshine Act, FDA, data privacy, and more. Having comprehensive, accurate data simplifies and streamlines compliance, while helping organizations avoid regulatory sanctions and reputational damage, saving both time and money.

We believe you should focus on developing life-saving therapies faster, tapping into current technologies to streamline clinical trials and approval processes. Over the last 12 years, we have supported nearly 75 life sciences leaders—across R&D, manufacturing, sales and marketing, payers, and partners—with the first cloud-native MDM SaaS platform.

Let us help reduce your effort to gather the mission-critical data you need, resolve core data accuracy issues, and fuel analytical systems with accurate, insight-ready data. Enabling you to save time, speed innovation, and lower costs—and get life-saving therapies to those who need them faster.

“When we launch new products, the first place we go is to the MDM platform. The ability to identify the customers for the new launch is super simple because we have all the functionalities and the features available in Reltio to do that.”

– **Manager of business operations and services, pharmaceutical**

The Total Economic Impact™ Of The Reltio Master Data Management Platform, a commissioned study conducted by Forrester Consulting on behalf of Reltio, September 2022

ABOUT RELTIO

At Reltio, we believe data should fuel business success. Reltio’s cloud-native master data management (MDM) SaaS platform unifies—in real time—core data from multiple sources into a single source of trusted information. Leading enterprise brands—from more than 140 countries spanning multiple industries—rely on our award-winning solution to turn data into their most valuable asset.

To learn more, visit www.reltio.com

US +1 (855) 360-3282
UK +44 (800) 368-7643

 @Reltio

 facebook.com/ReltioHub

 linkedin.com/company/reltio-inc